Analyzing Corvus Pharmaceuticals (NASDAQ:CRVS) & (OGXI)

Corvus Pharmaceuticals (NASDAQ: CRVS) and (NASDAQ:OGXI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Earnings and Valuation

This table compares Corvus Pharmaceuticals and ‘s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Corvus Pharmaceuticals N/A N/A -$52.36 million ($2.58) -4.53

Analyst Recommendations

This is a summary of recent ratings and target prices for Corvus Pharmaceuticals and , as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals 0 0 4 0 3.00
0 0 0 0 N/A

Corvus Pharmaceuticals presently has a consensus price target of $22.67, indicating a potential upside of 94.06%.

Institutional & Insider Ownership

82.7% of Corvus Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Corvus Pharmaceuticals and ‘s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals N/A -42.03% -39.36%

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

What are top analysts saying about Corvus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corvus Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit